135 related articles for article (PubMed ID: 21856317)
1. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats.
Rodefer JS; Saland SK; Eckrich SJ
Neuropharmacology; 2012 Mar; 62(3):1182-90. PubMed ID: 21856317
[TBL] [Abstract][Full Text] [Related]
2. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats.
Rodefer JS; Murphy ER; Baxter MG
Eur J Neurosci; 2005 Feb; 21(4):1070-6. PubMed ID: 15787711
[TBL] [Abstract][Full Text] [Related]
3. Environmental enrichment ameliorates phencyclidine-induced cognitive deficits.
Saland SK; Rodefer JS
Pharmacol Biochem Behav; 2011 May; 98(3):455-61. PubMed ID: 21334364
[TBL] [Abstract][Full Text] [Related]
4. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
Pedersen CS; Goetghebeur P; Dias R
J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
[TBL] [Abstract][Full Text] [Related]
5. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Hebb AL; Robertson HA; Denovan-Wright EM
Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
8. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility.
Wass C; Svensson L; Fejgin K; Pålsson E; Archer T; Engel JA; Klamer D
Pharmacol Biochem Behav; 2008 May; 89(3):352-9. PubMed ID: 18321564
[TBL] [Abstract][Full Text] [Related]
10. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
11. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine.
Andersen JD; Pouzet B
Neuropsychopharmacology; 2004 Jun; 29(6):1080-90. PubMed ID: 14970828
[TBL] [Abstract][Full Text] [Related]
12. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.
Goetghebeur P; Dias R
Psychopharmacology (Berl); 2009 Jan; 202(1-3):287-93. PubMed ID: 18392753
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
14. Subchronic phencyclidine in rats: alterations in locomotor activity, maze performance, and GABA(A) receptor binding.
Beninger RJ; Beuk J; Banasikowski TJ; van Adel M; Boivin GA; Reynolds JN
Behav Pharmacol; 2010 Feb; 21(1):1-10. PubMed ID: 19949321
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase inhibitors--are they potential neuroleptic drugs?
Becker A; Grecksch G
Behav Brain Res; 2008 Jan; 186(2):155-60. PubMed ID: 17854922
[TBL] [Abstract][Full Text] [Related]
16. [Executive functioning in unipolar depression: a review].
Fossati P; Ergis AM; Allilaire JF
Encephale; 2002; 28(2):97-107. PubMed ID: 11972136
[TBL] [Abstract][Full Text] [Related]
17. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.
Abdul-Monim Z; Reynolds GP; Neill JC
Behav Brain Res; 2006 May; 169(2):263-73. PubMed ID: 16500717
[TBL] [Abstract][Full Text] [Related]
18. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia.
Stefani MR; Moghaddam B
Biol Psychiatry; 2005 Feb; 57(4):433-6. PubMed ID: 15705361
[TBL] [Abstract][Full Text] [Related]
19. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
Mouri A; Noda Y; Noda A; Nakamura T; Tokura T; Yura Y; Nitta A; Furukawa H; Nabeshima T
Mol Pharmacol; 2007 Jun; 71(6):1598-609. PubMed ID: 17344353
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
